SCHEDULE 13G/A: Baker Bros. Advisors Amends Candel Therapeutics Stake, Reports 4.99% Beneficial Ownership
Beneficial Ownership Disclosure Amendment
Baker Bros. Advisors LP and its affiliates have filed an Amendment No. 1 to their Schedule 13G, disclosing a 4.99% beneficial ownership stake in Candel Therapeutics, Inc. as of March 31, 2025.
Summary
- Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, and Felix J. Baker (collectively, the "Reporting Persons") filed an Amendment No. 1 to their Schedule 13G regarding their beneficial ownership in Candel Therapeutics, Inc.
- As of March 31, 2025, the Reporting Persons collectively beneficially own 2,455,108 shares of Candel Therapeutics, Inc. Common Stock.
- This ownership represents 4.99% of the outstanding Common Stock of Candel Therapeutics, Inc.
- The beneficial ownership consists of 2,437,189 shares directly held by Baker Brothers Life Sciences, L.P. and 667, L.P. (the "Funds"), and 17,919 shares issuable upon exercise of Pre-funded Warrants within 60 days of the filing date.
- The calculation of the percentage is based on 47,235,460 shares outstanding as of March 6, 2025, plus 1,947,192 Common Shares issued from the net exercise of 1,949,999 Pre-funded Warrants by the Funds on March 28, 2025.
- The Pre-funded Warrants are subject to a beneficial ownership limitation, restricting exercise if it would result in ownership exceeding 4.99% of outstanding Common Stock, though this limit can be increased to 19.99% with 61 days' notice to the Issuer.
Sentiment
Score: 5
Explanation: A Schedule 13G filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or outlook. It is a neutral regulatory update.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of a significant investor's stake in a publicly traded company, common in the biotech sector where specialized funds like Baker Bros. Advisors often take substantial positions. It reflects a continued investment by a prominent life sciences investor.
Stakeholder Impact
- Shareholders: The filing indicates that Baker Bros. Advisors, a notable life sciences investor, maintains a significant stake (4.99%) in Candel Therapeutics, which could be interpreted as a continued vote of confidence in the company's long-term prospects by a sophisticated investor.
Key Dates
| Date | Description |
|---|---|
| 2025-03-06 | Date as of which 47,235,460 shares of Common Stock were reported outstanding in the Issuer's Form 10-K. |
| 2025-03-13 | Date Candel Therapeutics, Inc. filed its Form 10-K with the SEC. |
| 2025-03-28 | Date of net exercise by the Funds of 1,949,999 Pre-funded Warrants, resulting in 1,947,192 Common Shares issued. |
| 2025-03-31 | Date of event which requires filing of this statement (beneficial ownership snapshot date). |
| 2025-05-15 | Date the Amendment No. 1 to Schedule 13G was signed and filed. |
Keywords
Candel Therapeutics, Baker Bros. Advisors, Schedule 13G, Beneficial Ownership, Common Stock, Pre-funded Warrants, Biotechnology Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.